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Background
In the phase IIb Step study, vaccinees with baseline Ad5-
specific neutralizing antibodies (NAbs) exhibited a poten-
tial increased rate of HIV-1 acquisition as compared with
placebo controls. We sought to evaluate whether baseline
Ad5 NAbs correlated with NAbs to non-type C rare Ad
serotypes and whether baseline NAbs to rare Ad serotypes
correlated with enhancement of HIV-1 acquisition after
rAd5-gag/pol/nef vaccination.
Methods
In a case-controlled study, baseline sera from 81 cases
who acquired HIV-1 infection during the Step study (52
vaccinees and 29 placebo recipients) and 324 non-cases
who did not acquire HIV-1 infection (208 vaccinees and
29 placebo recipients) were evaluated for Ad5, Ad26,
Ad35, and Ad48 NAb titers. Non-cases were randomly
selected and matched for treatment arm, Ad5 serostatus,
circumcision status, and geographic region.
Results
Baseline Ad5 seroprevalence was 58% in these samples
with a median titer of 702. In contrast, baseline Ad26,
Ad35, and Ad48 seroprevalence was 14%, 6%, and 17%,
respectively, with median titers of 49, 47, and 46. There
were no correlations between baseline Ad5 NAbs and
Ad26/35/48 NAbs (P = 0.44–0.77, Spearman rank corre-
lation tests). Moreover, there were no differences observed
in baseline Ad26/35/48 NAbs between cases and non-
cases (P = 0.46–0.97, Wilcoxon rank sum tests).
Conclusion
Ad5 NAbs and Ad26/35/48 NAbs were independent vari-
ables that did not co-segregate, indicating that Ad5 NAbs
were not a surrogate marker for and did not predict NAbs
to these rare Ad serotypes. In addition, no increased HIV-
1 acquisition was observed in subjects with baseline
Ad26/35/48 NAbs following rAd5 vaccination. These data
suggest that cross-reactive immunity against heterologous
Ad serotypes did not contribute to increased HIV-1 sus-
ceptibility in this study. These findings have important
implications for the development of rare serotype Ad vec-
tor-based vaccines for HIV-1.
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